Cargando…

Diurnal Variation of Real-Life Insulin Sensitivity Factor Among Children and Adolescents With Type 1 Diabetes Using Ultra-Long-Acting Basal Insulin Analogs

BACKGROUND: Estimation of insulin sensitivity factor (ISF) is essential for correction insulin doses calculation. This study aimed to assess real-life ISF among children and adolescents with type 1 diabetes using ultra-long-acting basal insulin analogs and to detect factors associated with ISF among...

Descripción completa

Detalles Bibliográficos
Autor principal:	Hegab, Ahmed M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pediatrics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8957904/ https://www.ncbi.nlm.nih.gov/pubmed/35350271 http://dx.doi.org/10.3389/fped.2022.854972

Ejemplares similares

Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
por: Jonassen, Ib, et al.
Publicado: (2012)

Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs
por: Poon, Kitty, et al.
Publicado: (2010)

Cardiovascular safety of long‐acting insulin analogs in type 2 diabetes patients: Is there a better basal insulin?
por: Chang, Chia‐Hsuin, et al.
Publicado: (2017)

In search of the ideal basal insulin: Does the new‐generation ultra‐long‐acting insulin, degludec, provide the answer?
por: Hui, Elaine, et al.
Publicado: (2013)

Modern basal insulin analogs: An incomplete story
por: Singh, Awadhesh Kumar, et al.
Publicado: (2014)

Insulin Basal Dose Is Associated With Better Metabolic Control in Type 1 Diabetes Children and Adolescents
por: Arellano-Llamas, Abril, et al.
Publicado: (2021)

Insulin Degludec: A Significant Advancement in Ultralong-Acting Basal Insulin
por: Kalra, Sanjay
Publicado: (2013)

Concepts and clinical use of ultra-long basal insulin
por: Eliaschewitz, Freddy Goldberg, et al.
Publicado: (2016)

SAT-245 Estimated Insulin Sensitivity Score Predicts Post-OSTT Insulin Secretion and GI Hormone Differences in Adolescents with Obesity and PCOS
por: Garcia Reyes, Yesenia, et al.
Publicado: (2019)

Diurnal Pattern to Insulin Secretion and Insulin Action in Healthy Individuals
por: Saad, Ahmed, et al.
Publicado: (2012)

Insulin Degludec, a Novel Ultra-Long-Acting Basal Insulin versus Insulin Glargine for the Management of Type 2 Diabetes: A Systematic Review and Meta-Analysis
por: Zhou, Wenchuan, et al.
Publicado: (2019)

Rev-erb in GABAergic Neurons Controls Diurnal Hepatic Insulin Sensitivity
por: Ding, Guolian, et al.
Publicado: (2021)

Diagnostic Value of Diurnal Variability of Orthostatic Heart Rate Increment in Children and Adolescents With POTS
por: Cai, Hong, et al.
Publicado: (2021)

Real world outcomes of adding rapid-acting insulin versus switching to analog premix insulin among US patients with type 2 diabetes treated with insulin glargine
por: Miao, Raymond, et al.
Publicado: (2013)

Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing
por: Nishimura, Erica, et al.
Publicado: (2021)

Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?
por: Nasrallah, Sami N., et al.
Publicado: (2012)

Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review
por: Wang, Fei, et al.
Publicado: (2012)

A New-Generation Ultra-Long-Acting Basal Insulin With a Bolus Boost Compared With Insulin Glargine in Insulin-Naïve People With Type 2 Diabetes: A randomized, controlled trial
por: Heise, Tim, et al.
Publicado: (2011)

Comparative Pharmacokinetics and Insulin Action for Three Rapid-Acting Insulin Analogs Injected Subcutaneously With and Without Hyaluronidase
por: Morrow, Linda, et al.
Publicado: (2013)

Diurnal variation of carbohydrate insulin ratio in adult type 1 diabetic patients treated with continuous subcutaneous insulin infusion
por: Nakamura, Tomoaki, et al.
Publicado: (2014)

Predicting the Optimal Basal Insulin Infusion Pattern in Children and Adolescents on Insulin Pumps
por: Holterhus, Paul-Martin, et al.
Publicado: (2013)

Ultra-Rapid-Acting Insulins: How Fast Is Really Needed?
por: Wong, Eva Y., et al.
Publicado: (2021)

Concentrated insulins: the new basal insulins
por: Lamos, Elizabeth M, et al.
Publicado: (2016)

iGlarLixi versus basal plus Rapid‐Acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: The SoliSimplify Real‐World study
por: McCrimmon, Rory J., et al.
Publicado: (2022)

Insulin Analogs and Cancer
por: Sciacca, Laura, et al.
Publicado: (2012)

Treatment of Type 1 and Type 2 Diabetes Mellitus with Insulin Detemir, a Long-Acting Insulin Analog
por: Young, Jason R., et al.
Publicado: (2010)

A Real-World Anti-Diabetes Medication Cost Comparison Between Premixed Insulin Analogs and Long-Acting Insulin Analogs in Chinese Patients with Type 2 Diabetes: A Retrospective Database Analysis
por: Gao, Yue, et al.
Publicado: (2018)

Much Ado About Nothing? A Real-World Study of Patients with Type 2 Diabetes Switching Basal Insulin Analogs
por: Wei, Wenhui, et al.
Publicado: (2014)

Review of Insulin Resistance in Dilated Cardiomyopathy and Implications for the Pediatric Patient Short Title: Insulin Resistance DCM and Pediatrics
por: Mak, Daniel, et al.
Publicado: (2021)

Investigation of the Physico-Chemical Properties that Enable Co-Formulation of Basal Insulin Degludec with Fast-Acting Insulin Aspart
por: Havelund, Svend, et al.
Publicado: (2015)

Vascular effects of rapid-acting insulin analogs in the diabetic patient: a review
por: Fordan, Steve, et al.
Publicado: (2009)

Degludec insulin: A novel basal insulin
por: Kalra, Sanjay, et al.
Publicado: (2011)

Effects of Ultra-Long-Acting Insulin Compared to Long-Acting Insulin on Diabetic Ketoacidosis Incidence in Type 1 Diabetes Mellitus Patients
por: Alsofiani, Wafa A, et al.
Publicado: (2022)

An ultra‐long‐acting recombinant insulin for the treatment of diabetes mellitus in cats
por: Gilor, Chen, et al.
Publicado: (2021)

Ultra‐long‐acting recombinant insulin for the treatment of diabetes mellitus in dogs
por: Hulsebosch, Sean E., et al.
Publicado: (2022)

Efficacy and safety of switching to insulin glulisine from other rapid-acting insulin analogs in children with type 1 diabetes
por: Urakami, Tatsuhiko, et al.
Publicado: (2015)

Addition of a single short-acting insulin bolus to basal insulin-supported oral therapy: a systematic review of data on the basal-plus regimen
por: Seufert, Jochen, et al.
Publicado: (2019)

Diurnal and other variations in blood glucose in intensive care unit patients receiving insulin infusions
por: Smith, S, et al.
Publicado: (2007)

A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin–Treated Patients With Type 2 Diabetes
por: Bergenstal, Richard M., et al.
Publicado: (2012)

Comparison of Glycemic Variability Associated With Insulin Glargine and Intermediate-Acting Insulin When Used as the Basal Component of Multiple Daily Injections for Adolescents With Type 1 Diabetes
por: White, Neil H., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_9940ranv4s55mih90de27hgd3i